Prana Biotechnology Ltd. (NASDAQ:PRAN) shares dropped 6.5% during trading on Thursday . The stock traded as low as $4.88 and last traded at $4.92, with a volume of 54,724 shares traded. The stock had previously closed at $5.26.

Separately, Zacks Investment Research upgraded shares of Prana Biotechnology from a “sell” rating to a “hold” rating in a report on Wednesday, August 3rd.

The stock has a 50-day moving average of $5.03 and a 200-day moving average of $4.09. The company’s market cap is $7.30 million.

Prana Biotechnology Limited (Prana) is an Australia-based development stage medical biotechnology Company. The Company is engaged in commercializing research into Alzheimer’s disease, Huntington disease and other major age-related degenerative disorders. The Company’s lead drug candidate, PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.